Randomized trials of rituximab added to CHOP in newly diagnosed previously untreated aggressive lymphomas
Trial . | Design/regimen . | Patients/diseases . | Diseases . | Significant results . |
|---|---|---|---|---|
| Coiffier et al69 (2002) | R-CHOP vs CHOP | 399 patients, aged 60-80 y, stage II-IV | REAL/WHO: DLBCL (84%), Burkitt, mantle-cell, marginal-zone, follicular lymphoma, SLL, Hodgkin lymphoma, B-cell lymphoma NOS, T-cell lymphoma | 2-y EFS*: R-CHOP 43% vs CHOP 61% (P = .002); 2-y OS: R-CHOP 70% vs CHOP 57% (P = .007) |
| Habermann et al72 (2003) | First randomization: R-CHOP vs CHOP; second randomization: MR vs no maintenance | 632 patients, aged >60 y | REAL/WHO: DLBCL | 2.7-y TTF favors R-CHOP (P = .025) and MR (P = .01); no difference in OS |
| Pfreundschuh et al73 (2004) | R-CHOP-like vs CHOP-like | 326 patients, aged 18-60 y, stage I (bulky), II-IV, low risk (IPI of 0-1) | REAL/WHO:DLBCL | 2-y TTF: R-CHOP-like 76% vs CHOP-like 60% (P<.001); 2-y OS: R-CHOP-like 94% vs CHOP-like 87% (P = .001) |
Trial . | Design/regimen . | Patients/diseases . | Diseases . | Significant results . |
|---|---|---|---|---|
| Coiffier et al69 (2002) | R-CHOP vs CHOP | 399 patients, aged 60-80 y, stage II-IV | REAL/WHO: DLBCL (84%), Burkitt, mantle-cell, marginal-zone, follicular lymphoma, SLL, Hodgkin lymphoma, B-cell lymphoma NOS, T-cell lymphoma | 2-y EFS*: R-CHOP 43% vs CHOP 61% (P = .002); 2-y OS: R-CHOP 70% vs CHOP 57% (P = .007) |
| Habermann et al72 (2003) | First randomization: R-CHOP vs CHOP; second randomization: MR vs no maintenance | 632 patients, aged >60 y | REAL/WHO: DLBCL | 2.7-y TTF favors R-CHOP (P = .025) and MR (P = .01); no difference in OS |
| Pfreundschuh et al73 (2004) | R-CHOP-like vs CHOP-like | 326 patients, aged 18-60 y, stage I (bulky), II-IV, low risk (IPI of 0-1) | REAL/WHO:DLBCL | 2-y TTF: R-CHOP-like 76% vs CHOP-like 60% (P<.001); 2-y OS: R-CHOP-like 94% vs CHOP-like 87% (P = .001) |
R-CHOP indicates rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; SLL, small lymphocytic lymphoma; NOS, not otherwise specified; EFS, event-free survival; OS, overall survival; TTF, time to treatment failure; MR, maintenance rituximab; IPI, International Prognostic Index.
Updated results at 5 years70 show 5-y EFS: R-CHOP 47% vs CHOP 29% (P < .001); 5-y OS R-CHOP 58% vs CHOP 45% (P = .007).